Patients with type 2 diabetes and obesity-related heart failure with preserved ejection fraction received weight loss and heart failure benefits with semaglutide, according to a study in the New England Journal of Medicine, mirroring the results of a study in The Lancet. “Consistency between the findings of the two trials provides greater reassurance that semaglutide is an efficacious treatment option with a favorable safety profile in a broad population" with HFpEF related to obesity, the researchers said.
Full Story: MedPage Today (free registration)